Study of Comparative Bioavailability Among Two Formulations Containing Hydroxyzine Hydrochloride in Healthy Volunteers After a Single Dose Administration

Eduardo A. JUNIOR 1,2*, Luciana F. DUARTE 1, Daniela A. de OLIVEIRA 1, Tatiane A.M. STEIN 1, Marina M. NAKAMURA 1, Moisés L.P. VANUNCI 1, Silvana F. de SOUZA 1, Eunice M. SUENAGA 3 & Alessandro de C. CRUZ 4

1 Scentryphar Clinical Research, Av. Barão de Itapura, 885, 13020-420, Campinas-SP, Brazil.
2 Unicamp - College of Medical Sciences - Department of Medical Clinic/Cardiologia, Rua Tessália Vieira de Camargo, 126, 13083-970, Barão Geraldo, Campinas-SP, Brazil.
3 NUBEC/ Nucleus of Bioequivalence and Clinical Research, 4SPDM/Association for Development of the Medicine, Rua Onze de Junho, 581, 04041-152, Vila Clementino, São Paulo-SP, Brazil.

SUMMARY. The study was performed to compare the bioavailability of two hydroxyzine hydrochloride 25 mg tablet formulation in 16 volunteers of both sexes. The study was conducted open with randomized two period crossover design and a two weeks wash out period. Plasma samples were obtained over a 96 h interval. Hydroxyzine concentrations were analyzed by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS). Bioequivalence between the products was determined by calculating 90 % confidence intervals (90 % I.C) for the ratio of AUC0-t, AUC0-inf and Cmax values for the test and reference products, using logarithmic transformed data. The 90 % confidence intervals were 81.89–105.85 %, 84.61–105.30 %, and 84.04–108.66 %, respectively. Since the 90 % confidence intervals for Cmax, AUC0-t and AUC0-inf were within the 80–125 % interval proposed by the Food and Drug Administration, it was concluded that the two hydroxyzine hydrochloride formulations are bioequivalent in their rate and extent of absorption.